Education
About Us
Working with TipRanks
Follow Us
LFTD Partners (LIFD)
OTHER OTC:LIFD
Top Page
LFTD Partners
(OTC:LIFD)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.50
▲(66.67% Upside)
LFTD Partners' overall stock score is primarily impacted by its financial challenges, including declining profitability and negative cash flows. Technical indicators suggest a bearish trend with potential volatility, while valuation metrics highlight unprofitability. The absence of earnings call data and corporate events means these factors do not influence the score.
LFTD Partners (LIFD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.00M
Dividend YieldN/A
Average Volume (3M)1.38K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth-21.72%
EPS Growth25.00%
CountryUS
Employees148
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding14,822,678
10 Day Avg. Volume3,614
30 Day Avg. Volume1,380
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.19
Price to Sales (P/S)0.19
P/FCF Ratio-5.69
Enterprise Value/Market Cap2.01
Enterprise Value/Revenue0.22
Enterprise Value/Gross Profit0.71
Enterprise Value/Ebitda-884.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
LFTD Partners Business Overview & Revenue Model
Company DescriptionLFTD Partners Inc., through its subsidiary, Lifted Made, manufactures and sells psychedelic products under its Silly Shruum brand and hemp-derived cannabinoid products under its Urb Finest Flowers brand. The company was formerly known as Acquired Sales Corp. and changed its name to LFTD Partners Inc. in September 2021. LFTD Partners Inc. was incorporated in 1986 and is headquartered in Jacksonville, Florida.
How the Company Makes MoneyLFTD Partners generates revenue through multiple streams, including the sale of consumer products, digital marketing services, and investments in high-growth companies. Key revenue streams include direct sales from its owned brands, online marketing services for third-party clients, and returns from equity investments in its portfolio companies. The company has established significant partnerships within the cannabis sector, allowing it to capitalize on the growing demand for cannabis-related products, while its digital marketing services cater to various industries, providing a steady income from service contracts. Additionally, strategic acquisitions of promising startups contribute to revenue growth and diversification of its income sources.
LFTD Partners Earnings Call Summary
Earnings Call Date:Aug 13, 2025
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Negative
The earnings call presented a mixed picture with notable efforts to launch new products and reduce expenses, but these were overshadowed by significant revenue declines, operating losses, and challenges in receivables. The competitive and regulatory environment continues to pose significant challenges to LFTD Partners.Q3-2024 Updates
Positive Updates
Launch of New Product Line
Launched the newest iteration of the flagship brand, Urb, featuring a Fly High theme with major initiatives to increase direct-to-retailer and direct-to-consumer online sales.
Expense Reduction Achievements
Reduced payroll expenses by 8% from Q1 '24 to Q2 '24 and another 8% from Q2 to Q3 '24. Professional fee expenses down 40% from Q1 to Q2 '24 and another 33% from Q2 to Q3.
Gross Margin Improvement
Excluding the effect of written-off inventory, gross margin as a percentage of net sales improved to 47% compared to 38%.
Negative Updates
Significant Revenue Decline
Consolidated net sales were $8.6 million, down 34% due to regulatory challenges, economic pressure on consumers, and increased competition.
Operating Loss
Reported an operating loss of $141,000 compared to operating income of $659,000 in the previous year.
Net Loss Reported
Net loss was $194,000 or $0.01 per share compared to net income of $617,000 or $0.04 per share.
Challenges in Receivables
Faced $864,000 of bad debt expense due to delayed payments from certain customers, impacting net receivables, net income, and earnings per share.
Company Guidance
During the LFTD Partners' Q3 2024 earnings call, several key metrics and strategic initiatives were discussed to address the current challenges and future prospects of the company. The company's consolidated net sales were reported at $8.6 million, a decline of 34% compared to the previous year, attributed to regulatory challenges and increased competition in the hemp-derived cannabinoid market. Despite these headwinds, the company has been proactive in reducing payroll expenses by 8% from Q1 to Q2 and another 8% from Q2 to Q3, along with a 40% reduction in professional fees from Q1 to Q2 and a further 33% reduction from Q2 to Q3. Furthermore, the company has reduced its CapEx from $747,000 in the previous year to $310,000 year-to-date. The operating loss for the quarter was $141,000, contrasting with an operating income of $659,000 in the same quarter of the previous year. The net loss was reported at $194,000 or $0.01 per share, compared to a net income of $617,000 or $0.04 per share in Q3 2023. The company's current ratio improved to 2.64, reflecting a focus on maintaining financial stability amidst industry challenges.LFTD Partners Financial Statement Overview
Summary
LFTD Partners faces significant financial challenges, with declining profitability and negative cash flows. While the balance sheet remains relatively stable with low leverage, the company must address operational inefficiencies and improve cash flow management to enhance financial health.Income Statement
LFTD Partners has experienced fluctuating revenue growth, with a recent TTM increase of 2.34% following a decline in the previous year. The company struggles with profitability, as indicated by negative net profit and EBIT margins in the TTM period, reflecting operational challenges. Historical data shows a decline in gross profit margin from 50.36% in 2021 to 32.38% in the TTM, highlighting pressure on cost management.45
Neutral
Balance Sheet
The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.12 in the TTM, indicating manageable debt levels. However, the return on equity has turned negative in the TTM, suggesting inefficiencies in generating returns on shareholders' equity. The equity ratio remains stable, reflecting a solid capital structure.55
Neutral
Cash Flow
Cash flow analysis reveals negative operating and free cash flows in the TTM, indicating liquidity challenges. Despite a positive free cash flow growth rate, the operating cash flow to net income ratio is negative, suggesting cash flow issues in covering net losses. The free cash flow to net income ratio is positive, indicating some ability to cover net losses with free cash flow.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.62M | 37.33M | 51.61M | 57.42M | 31.66M | 5.34M |
| Gross Profit | 11.28M | 12.75M | 19.70M | 20.99M | 15.94M | 1.94M |
| EBITDA | -9.10K | -1.50M | 3.35M | 10.31M | 7.40M | -1.45M |
| Net Income | -764.81K | -1.86M | 2.16M | 7.20M | 5.80M | -1.53M |
Balance Sheet | ||||||
| Total Assets | 48.08M | 47.32M | 51.35M | 41.13M | 39.42M | 27.83M |
| Cash, Cash Equivalents and Short-Term Investments | 2.12M | 2.15M | 4.36M | 3.72M | 1.60M | 439.08K |
| Total Debt | 4.38M | 4.51M | 4.49M | 1.86M | 1.34M | 3.91M |
| Total Liabilities | 11.16M | 9.81M | 12.53M | 6.59M | 11.96M | 6.21M |
| Stockholders Equity | 36.93M | 37.50M | 38.82M | 34.54M | 27.46M | 21.62M |
Cash Flow | ||||||
| Free Cash Flow | -1.23M | -1.27M | -150.74K | 2.12M | 5.25M | -408.17K |
| Operating Cash Flow | -1.12M | -960.07K | 638.92K | 3.04M | 5.62M | -338.04K |
| Investing Cash Flow | -75.54K | -479.57K | -2.52M | -916.12K | -446.65K | -3.51M |
| Financing Cash Flow | -303.33K | -770.95K | 3.70M | -193.42K | -4.01M | -98.00K |
LFTD Partners Technical Analysis
Positive
0.30
Price Trends
0.27
Positive
0.30
Negative
0.34
Negative
Market Momentum
<0.01
Negative
59.54
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIFD, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.27, and below the 200-day MA of 0.34, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.54 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LIFD.
LFTD Partners Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $4.00M | -5.23 | -2.05% | ― | -21.72% | 25.00% | |
| ― | $8.47M | -0.15 | -33.13% | ― | -7.80% | 90.17% | |
| ― | $121.14M | ― | -381.09% | ― | 616.67% | -22.13% | |
| ― | $10.60M | ― | -36.94% | ― | 2.17% | 88.34% | |
| ― | $12.82M | ― | -230.73% | ― | -24.10% | 38.17% |
* Healthcare Sector Average
LIFD
LFTD Partners
0.30
-0.18
-37.50%
YCBD
cbdMD
0.95
-3.13
-76.72%
IMCC
IM Cannabis Corp
1.41
-0.67
-32.21%
FLGC
Flora Growth
10.35
-45.61
-81.50%
IXHL
Incannex Healthcare Limited Sponsored ADR
0.34
-1.93
-85.02%
AKAN
Akanda Corp
1.68
-2.83
-62.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.